Skip to content

Zidebactam Dihydrate

Published: July 26, 2026Updated: August 25, 2026

Zidebactam Dihydrate is a next-generation beta-lactamase inhibitor belonging to the diazabicyclononane (DBO) class. It is being developed in combination with cefepime to treat serious multi-drug resistant Gram-negative bacterial infections. This agent is particularly being investigated for its activity against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Quick summary

Zidebactam Dihydrate is an investigational beta-lactamase inhibitor combined with cefepime for treating resistant Gram-negative infections.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

RxNorm
2744814
Generic
Zidebactam Dihydrate
Class
pin-variant
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Being developed for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) caused by multi-drug resistant Gram-negative pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).

Functions as a dual-action inhibitor by binding to penicillin-binding proteins (particularly PBP2) and inhibiting serine-beta-lactamases including ESBLs, AmpC, and KPC-type carbapenemases. When combined with cefepime, it restores and extends the activity of the beta-lactam backbone against resistant organisms.

This is an investigational medication still undergoing clinical development. Safety and efficacy profiles are being established through clinical trials. As a beta-lactamase inhibitor, it is always used in combination with a beta-lactam antibiotic and is not administered as monotherapy.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy